cdca8 Antibody

What is the biological function of CDCA8 and why is it important to study?

CDCA8 is a component of the chromosomal passenger complex that ensures proper chromosome segregation during mitosis. It plays a vital role in maintaining genomic stability through regulating mitotic events. Research indicates CDCA8 is significantly upregulated in 23 cancer types compared to normal tissues , making it a protein of interest in cancer biology. It has been specifically implicated in hepatocellular carcinoma (HCC) , thyroid cancer , lung adenocarcinoma, and skin cutaneous melanoma progression . Its overexpression correlates with poorer survival outcomes in multiple cancer types, highlighting its importance as both a prognostic marker and potential therapeutic target for cancer treatment.

What are the recommended applications for CDCA8 antibodies in cancer research?

CDCA8 antibodies have been validated for several research applications including:

• Western blotting (WB) for detecting CDCA8 protein expression in cell lysates

• Immunohistochemistry (IHC-P) for visualizing CDCA8 expression in tissue samples

• ELISA for quantitative analysis of CDCA8 levels

For optimal results, researchers should use dilutions of 1:500-1:1000 for WB and 1:50-1:100 for IHC-P applications . These antibodies have demonstrated reactivity against human, mouse, and rat samples, making them versatile tools for comparative oncology studies across species models .

How can I validate the specificity of a CDCA8 antibody for my research?

To validate CDCA8 antibody specificity:

• Perform positive control tests using tissues known to express CDCA8 (e.g., mouse testis has been identified as a positive control sample)

• Include CDCA8 knockdown/silenced cells as negative controls (using siRNA or shRNA approaches)

• Verify a single band of appropriate molecular weight in Western blot applications

• Compare antibody staining patterns with mRNA expression data from RT-PCR

• Consider cross-validation with a second CDCA8 antibody raised against a different epitope

Research has shown that effective validation increases confidence in downstream experimental results, especially when examining differential expression between tumor and normal tissues .

What are the optimal experimental conditions for CDCA8 knockdown studies?

Based on published research protocols, optimal experimental conditions for CDCA8 knockdown studies include:

• siRNA transfection approach: Studies have successfully used three CDCA8-specific siRNA variants (CDCA8-1, -2, and -3) with CDCA8-1 and CDCA8-3 demonstrating higher growth suppression efficacy. Optimal conditions include:

  • Plating cells at 30% confluence 24 hours before transfection

  • Treatment with 15 nM siRNA mixed with equivalent amounts of cationic lipids

  • Evaluation of knockdown efficiency after 4 days of treatment

• shRNA lentiviral approach: For stable knockdown models:

  • Co-transfection of psPAX2, pMD2.G, and PLKO/shCDCA8 vectors into HEK293T cells to produce lentivirus

  • Transfection of target cancer cells at appropriate confluence for 24 hours

  • Selection with 2 μg/ml puromycin for 7 days to establish stable expression

  • Verification of knockdown efficiency using qPCR and Western blotting

These approaches have demonstrated significant inhibition of cancer cell proliferation and other malignant phenotypes in multiple studies .

What are the key downstream effects to monitor after CDCA8 manipulation in cancer cells?

When investigating the consequences of CDCA8 manipulation, researchers should monitor:

• Cellular proliferation: Using MTT assays or other proliferation measurements (studies have demonstrated significant growth inhibition after CDCA8 knockdown)

• Colony formation capacity: Significant reductions in colony counts have been observed with CDCA8 silencing

• Apoptosis rates: Flow cytometry analysis for apoptotic cell percentage (CDCA8 knockdown cells showed higher apoptotic rates)

• Cell migration ability: Migration assays to assess metastatic potential

• Expression of key signaling molecules:

  • Apoptosis-related proteins: Bax, caspase 3, CD40, CD40L, Fas, FasL, p21, p27, survivin, XIAP

  • Cell cycle regulatory proteins: CCND1, CDK4, CDK6

  • Signaling pathway components: Akt, p-Akt, β-catenin

• Cancer stem cell markers: CD133 expression (CDCA8 knockdown decreased CD133 expression in HCC models)

These parameters comprehensively assess the functional impact of CDCA8 on cancer cell behavior and underlying mechanisms.

How can CDCA8 antibodies be utilized in cancer stem cell (CSC) research?

CDCA8 antibodies serve as valuable tools in CSC research through:

• CSC population identification and isolation: Research has demonstrated that CD133+ CSC populations sorted from PLC/PRF/5 cells by FACS exhibited significantly higher CDCA8 expression compared to CD133- populations . CDCA8 antibodies can help identify and characterize these CSC subpopulations.

• Functional studies of stemness regulation: CDCA8 knockdown decreased CD133 expression and inhibited spheroid formation in CD133+ cells, suggesting CDCA8 plays a role in maintaining stemness properties . Specifically:

  • CDCA8 silencing upregulated ATF3 and GADD34 in CD133+ CSCs

  • The treatment inactivated the AKT/β-catenin signaling axis

  • These molecular changes correlated with inhibition of growth and spheroid formation

• Therapeutic targeting validation: CDCA8 antibodies can track protein expression changes following experimental treatments, helping assess the efficacy of novel therapeutic approaches aimed at eliminating cancer stem cells .

These applications support investigation of CDCA8 as a potential therapeutic target not only for primary HCC treatment but also for prevention of metastasis or recurrence through CSC targeting .

What are the challenges in correlating CDCA8 expression with clinical outcomes in different cancer types?

Researchers face several challenges when correlating CDCA8 expression with clinical outcomes:

• Sample size limitations: Studies have shown conflicting results regarding CDCA8 correlation with tumor stage, with some showing significant associations while others have p-values approaching but not reaching significance . For example, in one thyroid cancer study, researchers found no significant correlation between CDCA8 expression and tumor stage (p=0.061), likely due to insufficient sample size .

• Tissue heterogeneity: CDCA8 expression varies within tumor tissues, requiring careful sample selection and standardized scoring methods. Published data from immunohistochemical analyses shows significant differences in CDCA8 expression between tumor and normal tissues:

  CDCA8 Expression	Tumor Tissue		Normal Tissue		P-value
  	Cases	Percentage	Cases	Percentage
  Low	17	42.5%	40	100%	<0.001
  High	23	57.5%	0	0%
  Total	40	100.0%	40	100.0%

• Demographic and clinical variables: Research indicates CDCA8 expression can vary based on multiple factors including age, gender, tumor infiltration level, and cancer stage, necessitating multivariate analysis approaches :

  Features	No. of patients	CDCA8 expression		P value
  		low	high
  Age (years)
  <40	19	10	9	0.223
  ≥40	21	7	14
  Gender
  Male	8	4	4	0.636
  Female	32	13	19
  T Infiltrate
  T1	2	1	1	0.563
  T2	24	9	15
  T3	10	6	4
  T4	4	1	3
  Stage
  I	24	13	11	0.061
  II	9	2	7
  III	3	1	2
  IV	4	0	4

• Integration of multi-omics data: Comprehensive assessment requires integration of CDCA8 protein expression, promoter methylation status, and mutational analysis across cancer types .

How can CDCA8 antibodies be used in investigating the mechanisms of treatment resistance in cancer?

CDCA8 antibodies can provide valuable insights into treatment resistance mechanisms through:

• Monitoring CDCA8 expression changes after therapy: Research suggests CDCA8 may play a role in determining treatment response. Antibodies can track expression before and after treatment to identify correlations with resistance development.

• Combination therapy assessment: When testing CDCA8-targeting approaches in combination with standard therapies, antibodies can verify target engagement and expression modulation. The CDCA8 signaling pathway interacts with multiple cancer-related pathways including Akt/β-catenin , suggesting potential synergistic therapeutic approaches.

• Cancer stem cell population tracking: As CDCA8 is implicated in cancer stem cell maintenance , antibodies can help monitor therapy-resistant CSC populations throughout treatment courses. Studies have shown that:

  • CD133+ CSC populations express higher levels of CDCA8

  • CDCA8 knockdown reduces stemness properties

  • This suggests targeting CDCA8 might overcome resistance mediated by CSCs

• Immune response correlation: Research indicates positive associations between CDCA8 expression and infiltrating immune cells, particularly CD8+ and CD4+ T cells . Antibodies can help investigate how CDCA8 levels correlate with immunotherapy response.

What are common technical issues when using CDCA8 antibodies and how can they be addressed?

Researchers working with CDCA8 antibodies may encounter these technical challenges:

• Background staining in IHC applications:

  • Optimize blocking conditions (use 5% BSA or serum matching secondary antibody species)

  • Increase washing steps between incubations

  • Titrate primary antibody concentrations (start with recommended 1:50-1:100 dilution)

  • Use antigen retrieval methods appropriate for CDCA8 detection in fixed tissues

• Multiple bands in Western blot:

  • Ensure sample preparation maintains protein integrity (use protease inhibitors)

  • Optimize primary antibody dilution (1:500-1:1000 recommended)

  • Include positive controls (mouse testis lysate has been validated)

  • Verify antibody specificity through knockdown controls

• Low signal intensity:

  • Consider cellular localization of CDCA8 (chromosome, cytoplasm, and nucleus) when optimizing extraction protocols

  • Extend primary antibody incubation time (overnight at 4°C often improves results)

  • Use enhanced chemiluminescence detection systems for Western blotting

  • For IHC, employ signal amplification systems like HRP-polymer detection

• Experimental variability:

  • Standardize antibody lots across experiments

  • Use recombinant CDCA8 protein standards for quantitative applications

  • Include consistent positive and negative controls

How can researchers effectively compare results across different CDCA8 antibodies and detection methods?

For effective cross-method and cross-antibody comparisons:

• Standardize detection methods:

  • Use the same positive controls across antibodies (mouse testis has been validated)

  • Apply consistent scoring systems for IHC (e.g., percentage of positive cells, staining intensity)

  • Normalize Western blot data to housekeeping proteins consistently

• Validate with orthogonal techniques:

  • Confirm protein expression findings with mRNA analysis (RT-PCR, RNA-seq)

  • Use multiple antibodies targeting different CDCA8 epitopes

  • Employ functional validation through knockdown/overexpression studies

• Address epitope differences:

  • Document antibody recognition sites (e.g., an antibody recognizing amino acids 1-280 of human CDCA8)

  • Consider whether post-translational modifications affect epitope accessibility

  • Account for potential isoform recognition differences

• Quantitative calibration:

  • Develop standard curves for quantitative applications

  • Use digital image analysis for IHC quantification

  • Apply statistical methods appropriate for inter-method comparisons

How might CDCA8 antibodies contribute to developing targeted cancer therapies?

CDCA8 antibodies can advance targeted therapy development through:

What are emerging research areas involving CDCA8 that may require specialized antibody applications?

Emerging research areas involving CDCA8 include:

• Single-cell analysis of CDCA8 expression: Understanding cellular heterogeneity in tumors requires antibodies compatible with single-cell technologies like mass cytometry or imaging mass cytometry.

• CDCA8 in liquid biopsies: Developing antibodies suitable for detecting circulating tumor cells or extracellular vesicles expressing CDCA8 could enable minimally invasive monitoring.

• Structural biology applications: Antibodies that recognize specific conformational states of CDCA8 may help elucidate its functional dynamics during mitosis and interactions with binding partners.

• Immune response modulation: Research has shown positive correlations between CDCA8 expression and infiltrating immune cells , suggesting potential applications in immuno-oncology studies requiring multiplex immunofluorescence approaches.

• Epigenetic regulation of CDCA8: Studies have identified reduced CDCA8 promoter methylation in cancer tissues compared to normal controls , indicating a need for antibodies specific to epigenetic modifiers that regulate CDCA8.